Selection of currently ongoing clinical pharmaceutical trials at the NCRC
Titel |
NCT-Number |
Recruitment status |
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis (HERCULES) |
NCT04411641 | activ |
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS) |
NCT04458051 | activ |
WN43194 Satralizumab phase iii (Meteoroid) |
in preparation | |
Study MOG001 (Parexel 247511) phase iii (CosMOG) |
in preparation |
Titel |
NCT-Number |
Recruitment status |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis |
NCT03920293 | activ |
Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis |
NCT04818671 | activ |
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis |
NCT04951622 | in preparation |
A Phase 3B, Randomized, Open-label, Parallel-Group Trial to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis | NCT04980495 | in preparation |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis |
NCT05218096 | in preparation |
Titel |
NCT-Number |
Recruitment status |
A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE) |
NCT04281472 | activ |
Gamunex® 10% Use in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN) in clinical Routine: Observational study to assess Individualized Treatment Decisions (I-GUIDE) |
Sponsor-Reg.GPN-001 | activ |